Overview

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Citalopram
Quetiapine Fumarate
Criteria
Inclusion Criteria:

- Male or female aged 18 to 65 years

- A documented diagnosis of major depressive disorder

Exclusion Criteria:

- Patients with a DSM IV Axis I disorder other than MDD within 6 months of enrolment

- Patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the
patient's current psychiatric status

- Patients whose current episode of depression exceeds 12 months or is less than 4 weeks
prior to enrolment